Programme
Wednesday 24 November 2021
Day 1 - New Modalities

UK time
(GMT)
Central European Time
(CET)
 
08.00 - 08.15 09.00 - 09.15 Welcome: Presentation of chairs, agenda, meeting logistics and technical point person (Auditorium)
Axel Pähler (Roche), Emre Isin (Servier), Lars Weidolf (AstraZeneca), Markus Walles (Novartis)
    Session: Biotransformation of tethered biotherapeutics
Chair: Markus Walles (Novartis)
08.15 - 08.45 09.15 - 09.45 Presentation 1: Antibody Drug Conjugates: Chemical design and biotransformation strategies regarding regulatory landscape (Auditorium)
Georges Da Violante (Servier)
08.45 - 09.15 09.45 - 10.15 Presentation 2: Overview of IND-enabling biotransformation studies supporting ADC programs at Novartis (Auditorium)
Christian Lanshoeft (Novartis)
09.15 - 10.15 10.15 - 11.15 Presentation 3: Biotransformation Studies with Peptides: In Vitro and In Vivo Case Studies and the use of Software Tools (Auditorium)
Mark Savage (YorkBio)
10.15 - 10.30 11.15 - 11.30 Coffee Break (15 minutes)
10.30 - 11.00 11.30 - 12.00 Breakout 1: Discussion/feedback on presentations (Breakout Rooms)
11.00 - 12.00 12.00 - 13.00 Lunch break
    Session: ASO
Chair: Lars Weidolf (AstraZeneca)
12.00 - 12.30 13.00 - 13.30 Presentation 4: Investigations on the biotransformation of antisense oligonucleotides (ASOs) in vitro and in vivo (Auditorium)
Andreas Brink (Roche)
12.30 - 13.00 13.30 - 14.00 Presentation 5: In vivo cross species biotransformation comparison of a conjugated ASO (Auditorium)
Xueqing Li (AstraZeneca)
13.30 - 14.00 14.30 - 15.00 Presentation 6: Automated data analysis of oligonucleotide metabolism data (Auditorium)
Bridget Becker (Covance)
14.00 - 14.30 15.00 - 15.30 Breakout 2: Discussion/Feedback on presentations (Breakout Rooms)
14.30 - 14.45 15.30 - 15.45 Coffee Break (15 minutes)
14.45 - 15.15 15.45 - 16.15 Share feedback from Breakout 1 and 2 (Auditorium)
Axel Pähler (Roche), Lars Weidolf (AZ), Markus Walles (Novartis), Emre Isin (Servier)
15.15 - 15.45 16.15 - 16.45 Panel discussion: How can CROs and Pharma drive the development of new modalities together? (Auditorium)
Angus Neddermann (YorkBio), Jelle Reinen (CRL), Caroline Andersson (Covance), Axel Pähler (Roche), Lars Weidolf (AZ), Markus Walles (Novartis), Emre Isin (Servier)
15.45 - 16.00 16.45 - 17.00 Meeting closure  (Auditorium)
Axel Pähler (Roche), Lars Weidolf (AZ), Markus Walles (Novartis), Emre Isin (Servier)
Thursday 25 November 2021
Day 2 - Small Molecules

UK time
(GMT)
Central European Time
(CET)
 
08.00 - 08.15 09.00 - 09.15 Introduction of day 2 (Auditorium)
Chair: Emre Isin (Servier)
08.15 - 09.00 09.15 - 10.00 Presentation 7 (Keynote): 42 years of biotransformation in 45 minutes (Auditorium)
Lars Weidolf (AstraZeneca)
09.00 - 09.30 10.00 - 10.30 Presentation 8: Modern perspectives on the historic QUAN/QUAL paradigm – a decade on, where are we now…? (Auditorium)
Dan Weston (GSK)
09.30 - 10.30 10.30 - 11.30 Presentation 9: Applied In vitro assays to study the hepatic metabolism of low turnover compounds (Auditorium)
Cross company (Boehringer, Bayer, Sanofi, Roche, Novartis) presentations (10 min each)
10.30 - 10.45 11.30 - 11.45 Coffee Break (15 minutes)
10.45 - 11.15 11.45 - 12.15 Breakout 3: Joined discussions on quantitation of metabolites and in vitro assays for compounds with low metabolic turn-over (Breakout Rooms)
11.15 - 12.30 12.15 - 13.30 Lunch break
    Session: Global cross company initiatives (Auditorium)
Chair: Axel Pähler (Roche)
12.30 - 13.00 13.30 - 14.00 Presentation 10: Medicine Microbiome Initiative (Auditorium)
Bernard Walther (Servier)
13.00 - 13.30 14.00 - 14.30 Presentation 11: Human ADME paradigm shift (Auditorium)
Graeme Young (GSK)
13.30 - 14.00 14.30 - 15.00 Breakout 4: Joined discussions on future designs of human ADME studies and microbiome investigations (Breakout Rooms)
14.00 - 14.15 15.00 - 15.15 Coffee Break (15 minutes)
14.15 - 14.45 15.15 - 15.45 Feedback from Breakout/Topics for next meeting (Auditorium)
Axel Pähler (Roche), Lars Weidolf (AZ), Markus Walles (Novartis), Emre Isin (Servier)
14.45 - 15.00 15.45 - 16.00 Farewell to Lars and meeting closure (Auditorium)
Axel Pähler (Roche), Emre Isin (Servier), Lars Weidolf (AstraZeneca), Markus Walles (Novartis)